2-13-22 Miyakojimahondori Miyakojima-ku, Osaka, 534-0021 Japan.
Anticancer Res. 2014 Mar;34(3):1245-9.
Intravenous bisphosphonates (BPs) have been used to reduce the frequency of skeletal-related events due to bone metastases of several kinds of cancers. Although many studies on BP-related atypical fractures (BRAFs) due to the use of BP for osteoporosis treatment have been reported, few reports on BRAFs arising as a complication of long-term BP use for bone metastasis of cancer are available.
A 62-year-old woman with a history of breast cancer presented with right thigh pain after she had a fall. Radiographs indicated a transverse fracture in the shaft of the right femur. She had been on zoledronate treatment for six years. Based on radiographic and histopathological findings, we concluded that the fracture was not a pathological fracture associated with metastasis but was a complication of long-term BP treatment.
Clinical oncologists should consider the possibility of BRAFs in patients on long-term zoledronate treatment for bone metastases.
静脉注射双膦酸盐(BPs)已被用于降低多种癌症骨转移引起的骨骼相关事件的频率。虽然已经报道了许多关于使用 BP 治疗骨质疏松症引起的 BP 相关非典型骨折(BRAFs)的研究,但很少有关于因癌症骨转移长期使用 BP 引起的 BRAFs 并发症的报告。
一名 62 岁女性,有乳腺癌病史,跌倒后出现右大腿疼痛。X 线片显示右股骨骨干的横向骨折。她已经接受唑来膦酸盐治疗六年了。根据影像学和组织病理学结果,我们得出结论,该骨折不是与转移相关的病理性骨折,而是长期 BP 治疗的并发症。
对于接受长期唑来膦酸盐治疗骨转移的患者,临床肿瘤学家应考虑发生 BRAFs 的可能性。